Patents by Inventor Wen-Chen SUEN

Wen-Chen SUEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10196665
    Abstract: This invention relates to a novel cell culture medium and methods to enhance recombinant antibody purity using the cell culture medium disclosed herein. The novel cell culture medium is a self-made feeding medium, which comprises from about 90 nM to about 500 mM cysteine, from about 50 mM to about 500 mM tyrosine, and from about 50 mM to about 300 tryptophan. This invention also relates to a method of growing cell culture using the cell culture medium disclosed herein By controlling the concentration of cysteine in the self-made feed medium as well as the amount and time of adding this feed medium into the cell culture, the purity of antibodies is significantly improved while glycosylation profile and antibody expression level are consistently maintained to guarantee the efficacy of antibodies.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 5, 2019
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xiwen Cheng, Chengwei Yan, Bin Yang, Wen-Chen Suen, Yuancan Weng, Chongfei Deng
  • Publication number: 20180030495
    Abstract: This invention relates to a novel cell culture medium and methods to enhance recombinant antibody purity using the cell culture medium disclosed herein. The novel cell culture medium is a self-made feeding medium, which comprises from about 90 nM to about 500 mM cysteine, from about 50 mM to about 500 mM tyrosine, and from about 50 mM to about 300 tryptophan. This invention also relates to a method of growing cell culture using the cell culture medium disclosed herein By controlling the concentration of cysteine in the self-made feed medium as well as the amount and time of adding this feed medium into the cell culture, the purity of antibodies is significantly improved while glycosylation profile and antibody expression level are consistently maintained to guarantee the efficacy of antibodies.
    Type: Application
    Filed: January 13, 2017
    Publication date: February 1, 2018
    Applicant: Sunshine Lake Pharma Co., Ltd.
    Inventors: Xiwen CHENG, Chengwei YAN, Bin YANG, Wen-Chen SUEN, Yuancan WENG, Chongfei DENG